Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
22 06 2021
Historique:
received: 12 08 2020
accepted: 29 12 2020
pubmed: 19 1 2021
medline: 6 8 2021
entrez: 18 1 2021
Statut: ppublish

Résumé

Sudden cardiac death (SCD) is an appalling complication of hypertrophic cardiomyopathy (HCM). There is an ongoing discussion about the optimal SCD risk stratification strategy since established SCD risk models have suboptimal discriminative power. The aim of this study was to evaluate the prognostic value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for SCD risk stratification compared to the European Society of Cardiology (ESC) SCD risk score and traditional risk factors in an >10-year follow-up. Two hundred and twenty consecutive patients with HCM and LGE-CMR were enrolled. Follow-up data were available in 203 patients (median age 58 years, 61% male) after a median follow-up period of 10.4 years. LGE was present in 70% of patients with a median LGE amount of 1.6%, the median ESC 5-year SCD risk score was 1.84. In the overall cohort, SCD rates were 2.3% at 5 years, 4.8% at 10 years, and 15.7% at 15 years, independent from established risk models. An LGE amount of >5% left ventricular (LV) mass portends the highest risk for SCD with SCD prevalences of 5.5% at 5 years, 13.0% at 10 years, and 33.3% at 15 years. Conversely, patients with no or ≤5% LGE of LV mass have favourable prognosis. LGE-CMR in HCM patients allows effective 10-year SCD risk stratification beyond established risk factors. LGE amount might be added to established risk models to improve its discriminatory power. Specifically, patients with >5% LGE should be carefully monitored and might be adequate candidates for primary prevention implantable cardioverter-defibrillator during the clinical long-term course.

Identifiants

pubmed: 33458753
pii: 6103204
doi: 10.1093/ehjci/jeaa423
pmc: PMC8219365
doi:

Substances chimiques

Contrast Media 0
Gadolinium AU0V1LM3JT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

732-741

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

JACC Cardiovasc Imaging. 2016 Dec;9(12):1392-1402
pubmed: 27450876
J Cardiovasc Magn Reson. 2013 May 01;15:35
pubmed: 23634753
Lancet. 2013 Jan 19;381(9862):242-55
pubmed: 22874472
J Am Coll Cardiol. 2010 Sep 7;56(11):875-87
pubmed: 20667520
Am J Cardiol. 2019 Oct 15;124(8):1286-1292
pubmed: 31447011
J Am Coll Cardiol. 2004 Jun 16;43(12):2260-4
pubmed: 15193690
Radiology. 2001 Jan;218(1):215-23
pubmed: 11152805
J Am Coll Cardiol. 2009 Jul 14;54(3):242-9
pubmed: 19589437
Eur Heart J. 2014 Oct 14;35(39):2733-79
pubmed: 25173338
Eur Heart J. 2014 Aug 7;35(30):2010-20
pubmed: 24126876
J Thorac Cardiovasc Surg. 2018 Aug;156(2):750-759.e3
pubmed: 29735354
Am J Cardiol. 2015 Sep 1;116(5):757-64
pubmed: 26183790
F1000Res. 2016 Sep 07;5:
pubmed: 27635240
Am J Cardiol. 2012 Oct 15;110(8):1207-12
pubmed: 22762717
Circulation. 2018 Sep 25;138(13):e210-e271
pubmed: 29084733
J Am Coll Cardiol. 2018 Aug 21;72(8):857-870
pubmed: 30115224
Circulation. 2002 Oct 29;106(18):2322-7
pubmed: 12403661
J Cardiovasc Magn Reson. 2013 Oct 08;15:91
pubmed: 24103764
Circulation. 2014 Aug 5;130(6):484-95
pubmed: 25092278
J Am Coll Cardiol. 2002 Dec 18;40(12):2156-64
pubmed: 12505229
J Am Coll Cardiol. 2019 Nov 12;74(19):2333-2345
pubmed: 31699273
Eur Heart J. 2003 Nov;24(21):1965-91
pubmed: 14585256

Auteurs

Simon Greulich (S)

Department of Cardiology and Angiology, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.

Andreas Seitz (A)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Diana Herter (D)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Fabian Günther (F)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Sabine Probst (S)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Raffi Bekeredjian (R)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Meinrad Gawaz (M)

Department of Cardiology and Angiology, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.

Udo Sechtem (U)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Heiko Mahrholdt (H)

Department of Cardiology, Robert Bosch Medical Center, Auerbachstrasse 110, 70376 Stuttgart, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH